Gapping up
In reaction to strong earnings/guidance: BIOL +27.7%, IFMI +24.2%, XUE +12%, PEIX +10.7%, VSLR +9%, HRTG +8%, MLR +6.9%, AV +5.9%, RNDY +5.7%, CSIQ +5.2%, DAR +3.7%, MNK +3.3%, ALG +2.2%, COST +1.9%, SQNM +1.4%, BKCC +1.4%, TSE +1.3%, AXAS +1.2%, OSIR +1.1%, CIEN +1%, .
M&A news: PCYC +10% (AbbVie (ABBV) to acquire Pharmacyclics; transaction valued at $261.25 pershare), ARWR +8.5% (acquires Novartis' (NVS) RNAi R&D portfolio), INSM +3.9% (Daily Mail discusses takeover speculation in INSM; RHHBY, MRK, AZN are possible suitors), MNK +3.3% (will acquire Ikaria from a Madison Dearborn-led investor group in a transaction valued at ~$2.3 bln), MAC +2% (may be a takeover target by Simon Property Group (SPG), according to WSJ), GDP +1% (light volume but saw late-day gain following reports co could consider going private; downgraded by boutique firm this morning)
Select Bio/pharma related names showing strength: APPY +10.2%, AVEO +8.4%, KYTH +5.6%, ZIOP +5.3%, BIOC +3.8%, ARIA +3.5%, AEZS +3.3%, OREX +2.5%, CLRX +2.4%, CYTX +-3.5%
Select oil/gas related names showing strength: REXX +3.9%, SFY +3.8%, LINE +2.3%, WLT +2.3%, STO +1.3%
Other news: EYES +19% (announces successful first implants of the Argus II Retinal Prosthesis System at two new centers in Italy), TENX +11.6% (highlights two recently-published scientific articles on the potential benefits of its lead candidate, levosimendan, in patients undergoing cardiac surgery), NAVB +9.9% (Navidea Biopharma and Norgine BV affiliate SpePharm AG announce European Commercial Partnership regarding Lymphoseek, also reported earnings), ONCY +8.9% (announced that an oral presentation by the Company's research collaborators in Professor Kevin Harrington's lab at the Institute for Cancer Research), TGTX +7.3% (discloses terms of Global Collaboration with Checkpoint Therapeutics; to make an up-front payment of $500k), CPRX +4% (Amifampridine phosphate for the treatment of congenital myasthenic syndromes granted FDA Orphan Designation status), NBG +3.5% (strong EU mkts today), GLDD +2.9% (awarded ~$134.5 mln Army contract), SFM +1.8% (Sprouts Farmers Market announced the launch of a public offering of 15,847,800 shares of its common stock held by affiliates of Apollo Global Management), .
Analyst comments: CLDN +14.1% (initiated with a Buy at ROTH Capital, tgt $70), GDOT +5.4% (upgraded to Outperform from Neutral at Credit Suisse), DNKN +2.8% (upgraded to Buy from Neutral at Goldman), AEO +2.4% (upgraded to Buy from Neutral at B. Riley & Co; upgraded to Buy from Hold at Stifel), KAR +1.7% (initiated with a Buy at Sun Trust Rbsn Humphrey)
In reaction to strong earnings/guidance: BIOL +27.7%, IFMI +24.2%, XUE +12%, PEIX +10.7%, VSLR +9%, HRTG +8%, MLR +6.9%, AV +5.9%, RNDY +5.7%, CSIQ +5.2%, DAR +3.7%, MNK +3.3%, ALG +2.2%, COST +1.9%, SQNM +1.4%, BKCC +1.4%, TSE +1.3%, AXAS +1.2%, OSIR +1.1%, CIEN +1%, .
M&A news: PCYC +10% (AbbVie (ABBV) to acquire Pharmacyclics; transaction valued at $261.25 pershare), ARWR +8.5% (acquires Novartis' (NVS) RNAi R&D portfolio), INSM +3.9% (Daily Mail discusses takeover speculation in INSM; RHHBY, MRK, AZN are possible suitors), MNK +3.3% (will acquire Ikaria from a Madison Dearborn-led investor group in a transaction valued at ~$2.3 bln), MAC +2% (may be a takeover target by Simon Property Group (SPG), according to WSJ), GDP +1% (light volume but saw late-day gain following reports co could consider going private; downgraded by boutique firm this morning)
Select Bio/pharma related names showing strength: APPY +10.2%, AVEO +8.4%, KYTH +5.6%, ZIOP +5.3%, BIOC +3.8%, ARIA +3.5%, AEZS +3.3%, OREX +2.5%, CLRX +2.4%, CYTX +-3.5%
Select oil/gas related names showing strength: REXX +3.9%, SFY +3.8%, LINE +2.3%, WLT +2.3%, STO +1.3%
Other news: EYES +19% (announces successful first implants of the Argus II Retinal Prosthesis System at two new centers in Italy), TENX +11.6% (highlights two recently-published scientific articles on the potential benefits of its lead candidate, levosimendan, in patients undergoing cardiac surgery), NAVB +9.9% (Navidea Biopharma and Norgine BV affiliate SpePharm AG announce European Commercial Partnership regarding Lymphoseek, also reported earnings), ONCY +8.9% (announced that an oral presentation by the Company's research collaborators in Professor Kevin Harrington's lab at the Institute for Cancer Research), TGTX +7.3% (discloses terms of Global Collaboration with Checkpoint Therapeutics; to make an up-front payment of $500k), CPRX +4% (Amifampridine phosphate for the treatment of congenital myasthenic syndromes granted FDA Orphan Designation status), NBG +3.5% (strong EU mkts today), GLDD +2.9% (awarded ~$134.5 mln Army contract), SFM +1.8% (Sprouts Farmers Market announced the launch of a public offering of 15,847,800 shares of its common stock held by affiliates of Apollo Global Management), .
Analyst comments: CLDN +14.1% (initiated with a Buy at ROTH Capital, tgt $70), GDOT +5.4% (upgraded to Outperform from Neutral at Credit Suisse), DNKN +2.8% (upgraded to Buy from Neutral at Goldman), AEO +2.4% (upgraded to Buy from Neutral at B. Riley & Co; upgraded to Buy from Hold at Stifel), KAR +1.7% (initiated with a Buy at Sun Trust Rbsn Humphrey)